Participant Centered Active Surveillance for Adverse Event Following Measles Immunization in Gedeo Zone, Ethiopia, 2022. A Multi-center Open-label Randomized Control Trial

Sponsor
Dilla University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05803538
Collaborator
(none)
391
1
4
8.5
45.8

Study Details

Study Description

Brief Summary

Introduction Participant centered active adverse event following immunization (AEFI) surveillance can offer real time vaccine safety data and help in signal detection. Evidence showed that it is still difficult to get AEFI from passive reporting in Ethiopia. Vast novel method of enhanced AEFI surveillance has been practiced globally. However, those methods had serious limitations including the requirement of high resource and expertise. Hence, there is a need to find the most flexible low cost and integrated AEFI surveillance system. To the best of our knowledge, there has no published research in Ethiopia which compare Participant diary, SMS, and telephone interview for the purpose of active AEFI surveillance.

Objective: To assess participant centered active adverse event surveillance following measles immunization at Gedeo Zone health facilities, Ethiopia.

Method: An open randomized trial will be employed from October 1, 2022- December 1, 2023, at Gedio Zone health facilities. All parents, care givers/guardians whose child receive vaccine during the study period in the study site will be included in the study. A total of 391participants will be randomized to SMS, telephone interview or diary card group using random number generator on Excel. Every participant will be contacted on day seven to request them whether they experience any AEFI. Differences in proportions will compared using chi-square tests. A 0.05 level of significance will be used for all analyses. Independent sample t-tests will be used to compare the mean time (in days) required to collect complete AEFI data by SMS, telephone interview and diary card. Multinominal logistic regression analyses will be used assess the factors associated with effective use of tailored SMS, telephone interview and diary card for the AEFI active surveillance. To further investigate the association between the vaccine and the adverse events and factors associated with vaccine binary and multi variable logistic regression will be used.

Condition or Disease Intervention/Treatment Phase
  • Device: SMS, telephone interview or diary card
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
391 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Other
Official Title:
Participant Centered Active Surveillance for Adverse Event Following Measles Immunization in Gedeo Zone, Ethiopia, 2022. A Multi-center Open-label Randomized Control Trial
Anticipated Study Start Date :
May 15, 2023
Anticipated Primary Completion Date :
Dec 20, 2023
Anticipated Study Completion Date :
Jan 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: SMS

Device: SMS, telephone interview or diary card
SMS, telephone interview or diary card

Experimental: Telephone interview

Device: SMS, telephone interview or diary card
SMS, telephone interview or diary card

Experimental: Diary card

Device: SMS, telephone interview or diary card
SMS, telephone interview or diary card

Active Comparator: Usual Care

Device: SMS, telephone interview or diary card
SMS, telephone interview or diary card

Outcome Measures

Primary Outcome Measures

  1. Response rate [7 days]

    To compare response rate of tailored SMS, telephone interview and diary card for the AEFI active surveillance

Secondary Outcome Measures

  1. AEFI's reported from each group and feasibility of participant centered AEFI active surveillance [7days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Parents, care givers/guardians, whose child receive vaccine.

  • ≥18 years of age.

  • Willing to adhere to study procedures, which will include a randomization.

  • Willing to participate

Exclusion Criteria:
  • Unable to give informed consent because of cognitive impairment.

  • Those who are both illiterate and don't have mobile phone.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dilla University Hawassa Snnpr Ethiopia 419

Sponsors and Collaborators

  • Dilla University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dawit Getachew Getachew, Mr., Dilla University
ClinicalTrials.gov Identifier:
NCT05803538
Other Study ID Numbers:
  • ETDU005
First Posted:
Apr 7, 2023
Last Update Posted:
Apr 7, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dawit Getachew Getachew, Mr., Dilla University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 7, 2023